Sabela Bobillo

Hematologist

[Sabela Bobillo @sabobillo]

Excellent talk by @CwynKate

[Matt Wilson @mattwilson2287]

A tour de force from @CwynKate !

[Matt Wilson @mattwilson2287]

Check out our (+ @sabobillo @CwynKate) review on #CNSprophylaxis in this year's educational book
https://t.co/3eq1rMVIZ6

To be presented by @CwynKate in Controversies in Aggressive NHL educational session Sat 9.30

[Sabela Bobillo @sabobillo]

Enhorabuena @Maria_Bobillo y todo el equipo!!!

[Toby Eyre @tobyeyre82]

Choices, choices in R/R #FL #ASH22 #bispecifics

[Sabela Bobillo @sabobillo]

A real pleasure to work with three fantastic CNS lymphoma experts @CwynKate @JahanzaibKhwaja #AndresFerreri on this review 👇🏻https://t.co/WFxCPWAONl

[Kate Cwynarski @CwynKate]

A pleasure to work with ⁦@sabobillo⁩ ⁦@JahanzaibKhwaja⁩ & #AndresFerreri on our review of ‘Prevention and Management of secondary CNS lymphoma’
A challenging & contentious area with still much to do to improve outcome for our patients
#lymsm https://t.co/1hKsDyOgAU

[Sabela Bobillo @sabobillo]

@falchi_lorenzo @gilles_salles @SantoshVardhana @MSK_DeptOfMed Fantastic review!! Congratulations Lorenzo @falchi_lorenzo @gilles_salles @SantoshVardhana

[Jonathan Friedberg @DrJFriedberg]

Our @SWOG analysis of extranodal presentation in limited-stage DLBCL, demonstrating similar outcomes to nodal presentations when treated with response-adapted therapy. @DebbieMStephens @DrDanPersky https://t.co/NkXTHjn3b2

[Sabela Bobillo @sabobillo]

@JahanzaibKhwaja Congrats @JahanzaibKhwaja @CwynKate et al.Very interesting and informative paper!! Great work👏🏻👏🏻👏🏻

[Kate Cwynarski @CwynKate]

Review/meta-analysis:
#CAR -T in #PCNSL n=30 & #SCNSL n=98.
SIM CRS/ICANS.
PCNSL vs SCNSL:
70% vs 72% CRS any grade
13% vs 11% grade 3-4
53% vs 48% ICANS any grade
18% vs 26% grade 3-4
SIM RESPONSE:
56% vs 47% CR
37% for both in remission at 6/12
#lymsm https://t.co/W7KaERzaa3

[Toby Eyre @tobyeyre82]

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-… https://t.co/KBua6gUY6v

[Women in Lymphoma - [email protected] @WomenInLymphoma]

💜Thank you Kerry Savage @pammckay123 @sabobillo & @Dr_KatLewis - very engaging discussion & opportunity to discuss data, caveats, practice/doubts & plans for research/future.
Watch/re-watch👇here https://t.co/vw6YQlUf8A

[Women in Lymphoma - [email protected] @WomenInLymphoma]

💜 Here we go! Series 7 of #WiLingWednesdays continues on Oct 12 with a #debate on #CNSProphylaxis with Kerry Savage @BCCancer @pammckay123 @sabobillo @Dr_KatLewis
Registration 👇
https://t.co/xdtbMbAk88
💜Thanks to supporter @lymphomaOz & sponsors @JanssenANZ @SeagenGlobal

[Sabela Bobillo @sabobillo]

@amniebla @Hemato_Vhebron Thank you!!!

[Sabela Bobillo @sabobillo]

@Sidnavigare Thank you!!

[Sabela Bobillo @sabobillo]

A real pleasure to be involved in this with an amazing group of international experts! Thank you @tobyeyre82 for leading and coordinating this comprehensive review

[Chan Cheah @chanyooncheah]

Comprehensive review on CNS prophylaxis for diffuse large B-cell lymphoma just out in @TheLancetOncol led by @tobyeyre82 with contributions from @pammckay123 @mattwilson2287 @CwynKate @Dr_KatLewis Kerry Savage & Andres Ferreri.
please take a look
#lymSM
https://t.co/Rr1crP2IET

[Toby Eyre @tobyeyre82]

⏩⏩Just out in @TheLancetOncol

Pleased to shared a comprehensive overview of what we know (& don't know!) about CNS prophylaxis in #DLBCL. Big thanks to stellar team of global co-authors 🔥 #lymsm

CNS prophylaxis for diffuse large B-cell lymphoma https://t.co/1Wx7wl3X9H

[Dr. Michele Donato @MDonatoBMT]

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma @ASTCT @lymphomahub @TheEBMT @EHA_Hematology https://t.co/BhL73tpiUq

[Sabela Bobillo @sabobillo]

@evacb93 @Hemato_Vhebron Mucha suerte en esta nueva etapa!!!!

[Tim Fenske @timfenske]

10 major studies looking at CNS prophy in DLBCL. Only 1 (the smallest) positive. Who is still doing CNS prophy?

I still do IT MTX x4 if double hit based on Petrich (Blood 2014) showing OS benefit and for testicular (based on IELSG phase 2). Not for all CNS-IPI 4-6 though

[Sabela Bobillo @sabobillo]

@gloria_iacoboni @BloodAdvances @pebarba @KRejeski @G_Villacampa @AChiappella77 @amniebla @Kersten_MJ @amgarciasancho @MSubklewe Congrats Gloria!!!👏🏻👏🏻👏🏻👏🏻